Lanreotide
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
Description
Product Specs
Product Science Overview
Lanreotide was developed by Ipsen Pharmaceuticals and is marketed under the brand name Somatuline . It was first approved for use in the United States by the Food and Drug Administration (FDA) on August 30, 2007 . The drug is also approved in several other countries, including the United Kingdom, Australia, and Canada .
Lanreotide works by mimicking the action of somatostatin, thereby inhibiting the secretion of growth hormone and other hormones . This inhibition helps manage the symptoms of acromegaly and neuroendocrine tumors. The drug is available in a long-acting formulation, which allows for less frequent dosing compared to other treatments .
Lanreotide is indicated for:
- The long-term treatment of patients with acromegaly who have had an inadequate response to, or cannot be treated with, surgery and/or radiotherapy .
- The treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival .
- The treatment of adults with carcinoid syndrome to reduce the frequency of short-acting somatostatin analog rescue therapy .
Lanreotide has a bioavailability of approximately 80% and a protein binding rate of 78% . It is metabolized in the gastrointestinal tract and has an elimination half-life of 2 hours for the immediate-release formulation and 5 days for the sustained-release formulation . The drug is primarily excreted through the bile duct .
